{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:36:08Z","timestamp":1776436568998,"version":"3.51.2"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI127469"],"award-info":[{"award-number":["R01 AI127469"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI150739"],"award-info":[{"award-number":["U01 AI150739"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI141661"],"award-info":[{"award-number":["R01 AI141661"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AI159822"],"award-info":[{"award-number":["U19 AI159822"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["K99 AI153465"],"award-info":[{"award-number":["K99 AI153465"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["K99 AI153465"],"award-info":[{"award-number":["K99 AI153465"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI127469"],"award-info":[{"award-number":["R01 AI127469"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI150739"],"award-info":[{"award-number":["U01 AI150739"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI141661"],"award-info":[{"award-number":["R01 AI141661"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI127469"],"award-info":[{"award-number":["R01 AI127469"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AI159822"],"award-info":[{"award-number":["U19 AI159822"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI150739"],"award-info":[{"award-number":["U01 AI150739"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI141661"],"award-info":[{"award-number":["R01 AI141661"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P41GM103393"],"award-info":[{"award-number":["P41GM103393"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite recent success in hepatitis C virus (HCV) treatment using antivirals, an HCV vaccine is still needed to prevent reinfections in treated patients, to avert the emergence of drug-resistant strains, and to provide protection for people with no access to the antiviral therapeutics. The early production of broadly neutralizing antibodies (bNAbs) associates with HCV clearance. Several potent bNAbs bind a conserved HCV glycoprotein E2 epitope using an unusual heavy chain complementarity determining region 3 (HCDR3) containing an intra-loop disulfide bond. Isolation of additional structurally-homologous bNAbs would facilitate the recognition of key determinants of such bNAbs and guide rational vaccine design. Here we report the identification of new antibodies containing an HCDR3 disulfide bond motif using computational screening with the Rosetta software. Using the newly-discovered and already-known members of this antibody family, we review the required HCDR3 amino acid composition and propose determinants for the bent versus straight HCDR3 loop conformation observed in these antibodies.<\/jats:p>","DOI":"10.1038\/s41467-022-30865-9","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T10:03:24Z","timestamp":1654682604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2164-5698","authenticated-orcid":false,"given":"Nina G.","family":"Bozhanova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew I.","family":"Flyak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin P.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0892-9626","authenticated-orcid":false,"given":"Stormy E.","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Salas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Semi","family":"Rho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin G.","family":"Bombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1132-2550","authenticated-orcid":false,"given":"Luke","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinque","family":"Soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin R.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0049-1079","authenticated-orcid":false,"suffix":"Jr.","given":"James E.","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2277-3990","authenticated-orcid":false,"given":"Pamela J.","family":"Bjorkman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8945-193X","authenticated-orcid":false,"given":"Jens","family":"Meiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,8]]},"reference":[{"key":"30865_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-8976-8_1","volume":"1911","author":"DK Li","year":"2019","unstructured":"Li, D. K. & Chung, R. T. Overview of direct-acting antiviral drugs and drug resistance of hepatitis C virus. Methods Mol. Biol. 1911, 3\u201332 (2019).","journal-title":"Methods Mol. Biol."},{"key":"30865_CR2","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1002\/hep.25556","volume":"55","author":"MM Denniston","year":"2012","unstructured":"Denniston, M. M., Klevens, R. M., McQuillan, G. M. & Jiles, R. B. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001\u20132008. Hepatology 55, 1652\u20131661 (2012).","journal-title":"Hepatology"},{"key":"30865_CR3","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/474S2a","volume":"474","author":"L Gravitz","year":"2011","unstructured":"Gravitz, L. Introduction: a smouldering public-health crisis. Nature 474, S2\u2013S4 (2011).","journal-title":"Nature"},{"key":"30865_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nrd4050","volume":"12","author":"MP Manns","year":"2013","unstructured":"Manns, M. P. & von Hahn, T. Novel therapies for hepatitis C - one pill fits all? Nat. Rev. Drug Discov. 12, 595\u2013610 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"30865_CR5","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1002\/hep.27013","volume":"59","author":"WO Osburn","year":"2014","unstructured":"Osburn, W. O. et al. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology 59, 2140\u20132151 (2014).","journal-title":"Hepatology"},{"key":"30865_CR6","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.1073\/pnas.0607026104","volume":"104","author":"JM Pestka","year":"2007","unstructured":"Pestka, J. M. et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl Acad. Sci. USA 104, 6025\u20136030 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"30865_CR7","doi-asserted-by":"publisher","first-page":"e1007772","DOI":"10.1371\/journal.ppat.1007772","volume":"15","author":"ZY Keck","year":"2019","unstructured":"Keck, Z. Y. et al. Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design. PLoS Pathog. 15, e1007772 (2019).","journal-title":"PLoS Pathog."},{"key":"30865_CR8","doi-asserted-by":"publisher","first-page":"E82","DOI":"10.1073\/pnas.1718441115","volume":"115","author":"MC Mankowski","year":"2018","unstructured":"Mankowski, M. C. et al. Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Proc. Natl Acad. Sci. USA 115, E82\u2013E91 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"30865_CR9","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1172\/JCI130720","volume":"130","author":"VJ Kinchen","year":"2019","unstructured":"Kinchen, V. J. et al. Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance. J. Clin. Invest. 130, 4786\u20134796 (2019).","journal-title":"J. Clin. Invest."},{"key":"30865_CR10","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.tim.2018.04.002","volume":"26","author":"VJ Kinchen","year":"2018","unstructured":"Kinchen, V. J., Cox, A. L. & Bailey, J. R. Can broadly neutralizing monoclonal antibodies lead to a hepatitis C virus vaccine? Trends Microbiol. 26, 854\u2013864 (2018).","journal-title":"Trends Microbiol."},{"key":"30865_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nature12966","volume":"507","author":"BE Correia","year":"2014","unstructured":"Correia, B. E. et al. Proof of principle for epitope-focused vaccine design. Nature 507, 201\u2013206 (2014).","journal-title":"Nature"},{"key":"30865_CR12","doi-asserted-by":"publisher","first-page":"e92822","DOI":"10.1371\/journal.pone.0092822","volume":"9","author":"SC Lin","year":"2014","unstructured":"Lin, S. C., Liu, W. C., Jan, J. T. & Wu, S. C. Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses. PLoS ONE 9, e92822 (2014).","journal-title":"PLoS ONE"},{"key":"30865_CR13","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1172\/JCI78450","volume":"125","author":"JH Schickli","year":"2015","unstructured":"Schickli, J. H. et al. Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge. J. Clin. Invest. 125, 1637\u20131647 (2015).","journal-title":"J. Clin. Invest."},{"key":"30865_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nm1698","volume":"14","author":"M Law","year":"2008","unstructured":"Law, M. et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14, 25\u201327 (2008).","journal-title":"Nat. Med."},{"key":"30865_CR15","doi-asserted-by":"publisher","first-page":"6061","DOI":"10.1128\/JVI.02475-07","volume":"82","author":"ZY Keck","year":"2008","unstructured":"Keck, Z. Y. et al. Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J. Virol. 82, 6061\u20136066 (2008).","journal-title":"J. Virol."},{"key":"30865_CR16","doi-asserted-by":"crossref","unstructured":"Bailey, J. R. et al. Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. JCI Insight 2, e92872 (2017).","DOI":"10.1172\/jci.insight.92872"},{"key":"30865_CR17","doi-asserted-by":"publisher","first-page":"e0165047","DOI":"10.1371\/journal.pone.0165047","volume":"11","author":"SJ Merat","year":"2016","unstructured":"Merat, S. J. et al. Hepatitis C virus broadly neutralizing monoclonal antibodies isolated 25 years after spontaneous clearance. PLoS ONE 11, e0165047 (2016).","journal-title":"PLoS ONE"},{"key":"30865_CR18","doi-asserted-by":"crossref","unstructured":"Colbert, M. D. et al. Broadly neutralizing antibodies targeting new sites of vulnerability in hepatitis C virus E1E2. J. Virol. 93, e02070-18 (2019).","DOI":"10.1128\/JVI.02070-18"},{"key":"30865_CR19","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.immuni.2021.02.013","volume":"54","author":"F Chen","year":"2021","unstructured":"Chen, F. et al. Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins. Immunity 54, 781\u2013796 e4 (2021).","journal-title":"Immunity"},{"key":"30865_CR20","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1126\/science.1243876","volume":"342","author":"L Kong","year":"2013","unstructured":"Kong, L. et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science 342, 1090\u20131094 (2013).","journal-title":"Science"},{"key":"30865_CR21","doi-asserted-by":"publisher","first-page":"eaav1882","DOI":"10.1126\/sciadv.aav1882","volume":"5","author":"N Tzarum","year":"2019","unstructured":"Tzarum, N. et al. Genetic and structural insights into broad neutralization of hepatitis C virus by human VH1-69 antibodies. Sci. Adv. 5, eaav1882 (2019).","journal-title":"Sci. Adv."},{"key":"30865_CR22","doi-asserted-by":"crossref","unstructured":"Flyak, A. I. et al. An ultralong CDRH2 in HCV neutralizing antibody demonstrates structural plasticity of antibodies against E2 glycoprotein. Elife 9, e53169 (2020).","DOI":"10.7554\/eLife.53169"},{"key":"30865_CR23","doi-asserted-by":"publisher","first-page":"eabb5642","DOI":"10.1126\/sciadv.abb5642","volume":"6","author":"N Tzarum","year":"2020","unstructured":"Tzarum, N. et al. An alternate conformation of HCV E2 neutralizing face as an additional vaccine target. Sci. Adv. 6, eabb5642 (2020).","journal-title":"Sci. Adv."},{"key":"30865_CR24","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/B978-0-12-381270-4.00019-6","volume":"487","author":"A Leaver-Fay","year":"2011","unstructured":"Leaver-Fay, A. et al. ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol. 487, 545\u2013574 (2011).","journal-title":"Methods Enzymol."},{"key":"30865_CR25","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.chom.2018.10.009","volume":"24","author":"AI Flyak","year":"2018","unstructured":"Flyak, A. I. et al. HCV broadly neutralizing antibodies use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design. Cell Host Microbe 24, 703\u2013716 e3 (2018).","journal-title":"Cell Host Microbe"},{"key":"30865_CR26","doi-asserted-by":"publisher","first-page":"4446","DOI":"10.1073\/pnas.1518405113","volume":"113","author":"JR Willis","year":"2016","unstructured":"Willis, J. R. et al. Long antibody HCDR3s from HIV-naive donors presented on a PG9 neutralizing antibody background mediate HIV neutralization. Proc. Natl Acad. Sci. USA 113, 4446\u20134451 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"30865_CR27","doi-asserted-by":"crossref","unstructured":"Finn, J. A. et al. Identification of structurally related antibodies in antibody sequence databases using rosetta-derived position-specific scoring. Structure 28, 1124\u20131130.e5 (2020).","DOI":"10.1016\/j.str.2020.07.012"},{"key":"30865_CR28","doi-asserted-by":"crossref","unstructured":"Bozhanova, N. G. et al. Discovery of Marburg virus neutralizing antibodies from virus-naive human antibody repertoires using large-scale structural predictions. Proc. Natl Acad. Sci. USA 117, 31142\u201331148 (2020).","DOI":"10.1073\/pnas.1922654117"},{"key":"30865_CR29","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41586-019-0934-8","volume":"566","author":"C Soto","year":"2019","unstructured":"Soto, C. et al. High frequency of shared clonotypes in human B cell receptor repertoires. Nature 566, 398\u2013402 (2019).","journal-title":"Nature"},{"key":"30865_CR30","doi-asserted-by":"publisher","first-page":"E6946","DOI":"10.1073\/pnas.1614942113","volume":"113","author":"BG Pierce","year":"2016","unstructured":"Pierce, B. G. et al. Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: implications for vaccine design. Proc. Natl Acad. Sci. USA 113, E6946\u2013E6954 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"30865_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0065-3233(08)60520-3","volume":"34","author":"JS Richardson","year":"1981","unstructured":"Richardson, J. S. The anatomy and taxonomy of protein structure. Adv. Protein Chem. 34, 167\u2013339 (1981).","journal-title":"Adv. Protein Chem."},{"key":"30865_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9223","volume":"6","author":"T Ying","year":"2015","unstructured":"Ying, T. et al. Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nat. Commun. 6, 8223 (2015).","journal-title":"Nat. Commun."},{"key":"30865_CR33","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1080\/19420862.2016.1158370","volume":"8","author":"J Nowak","year":"2016","unstructured":"Nowak, J. et al. Length-independent structural similarities enrich the antibody CDR canonical class model. MAbs 8, 751\u2013760 (2016).","journal-title":"MAbs"},{"key":"30865_CR34","doi-asserted-by":"publisher","first-page":"e1501371","DOI":"10.1126\/sciadv.1501371","volume":"2","author":"TA Khan","year":"2016","unstructured":"Khan, T. A. et al. Accurate and predictive antibody repertoire profiling by molecular amplification fingerprinting. Sci. Adv. 2, e1501371 (2016).","journal-title":"Sci. Adv."},{"key":"30865_CR35","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","volume":"17","author":"JJ van Dongen","year":"2003","unstructured":"van Dongen, J. J. et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17, 2257\u20132317 (2003).","journal-title":"Leukemia"},{"key":"30865_CR36","unstructured":"Andrews, S. FastQC: A quality control tool for high throughput sequence data. Vol. 2017, https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/ (2010)."},{"key":"30865_CR37","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1093\/bioinformatics\/btx330","volume":"33","author":"JT Roehr","year":"2017","unstructured":"Roehr, J. T., Dieterich, C. & Reinert, K. Flexbar 3.0 - SIMD and multicore parallelization. Bioinformatics 33, 2941\u20132942 (2017).","journal-title":"Bioinformatics"},{"key":"30865_CR38","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1093\/bioinformatics\/btv401","volume":"31","author":"RC Edgar","year":"2015","unstructured":"Edgar, R. C. & Flyvbjerg, H. Error filtering, pair assembly and error correction for next-generation sequencing reads. Bioinformatics 31, 3476\u20133482 (2015).","journal-title":"Bioinformatics"},{"key":"30865_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-020-03649-5","volume":"21","author":"C Soto","year":"2020","unstructured":"Soto, C. et al. PyIR: a scalable wrapper for processing billions of immunoglobulin and T cell receptor sequences using IgBLAST. BMC Bioinforma. 21, 314 (2020).","journal-title":"BMC Bioinforma."},{"key":"30865_CR40","doi-asserted-by":"publisher","first-page":"W34","DOI":"10.1093\/nar\/gkt382","volume":"41","author":"J Ye","year":"2013","unstructured":"Ye, J., Ma, N., Madden, T. L. & Ostell, J. M. IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res. 41, W34\u2013W40 (2013).","journal-title":"Nucleic Acids Res."},{"key":"30865_CR41","doi-asserted-by":"publisher","first-page":"e59004","DOI":"10.1371\/journal.pone.0059004","volume":"8","author":"LG Nivon","year":"2013","unstructured":"Nivon, L. G., Moretti, R. & Baker, D. A Pareto-optimal refinement method for protein design scaffolds. PLoS ONE 8, e59004 (2013).","journal-title":"PLoS ONE"},{"key":"30865_CR42","unstructured":"Case, D. A. et al. AMBER 2020 (University of California, San Francisco, 2020)."},{"key":"30865_CR43","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1021\/acs.jctc.9b00591","volume":"16","author":"C Tian","year":"2020","unstructured":"Tian, C. et al. ff19SB: Amino-acid-specific protein backbone parameters trained against quantum mechanics energy surfaces in solution. J. Chem. Theory Comput. 16, 528\u2013552 (2020).","journal-title":"J. Chem. Theory Comput."},{"key":"30865_CR44","doi-asserted-by":"publisher","first-page":"9020","DOI":"10.1021\/jp8001614","volume":"112","author":"IS Joung","year":"2008","unstructured":"Joung, I. S. & Cheatham, T. E. Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations. J. Phys. Chem. B 112, 9020\u20139041 (2008).","journal-title":"J. Phys. Chem. B"},{"key":"30865_CR45","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1021\/jz501780a","volume":"5","author":"S Izadi","year":"2014","unstructured":"Izadi, S., Anandakrishnan, R. & Onufriev, A. V. Building water models: a different approach. J. Phys. Chem. Lett. 5, 3863\u20133871 (2014).","journal-title":"J. Phys. Chem. Lett."},{"key":"30865_CR46","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1021\/ct5010406","volume":"11","author":"CW Hopkins","year":"2015","unstructured":"Hopkins, C. W., Le Grand, S., Walker, R. C. & Roitberg, A. E. Long-time-step molecular dynamics through hydrogen mass repartitioning. J. Chem. Theory Comput. 11, 1864\u20131874 (2015).","journal-title":"J. Chem. Theory Comput."},{"key":"30865_CR47","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","volume":"23","author":"J-P Ryckaert","year":"1977","unstructured":"Ryckaert, J.-P., Ciccotti, G. & Berendsen, H. J. C. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 23, 327\u2013341 (1977).","journal-title":"J. Comput. Phys."},{"key":"30865_CR48","doi-asserted-by":"publisher","first-page":"5525","DOI":"10.1021\/acs.jctc.5b00743","volume":"11","author":"MK Scherer","year":"2015","unstructured":"Scherer, M. K. et al. PyEMMA 2: a software package for estimation, validation, and analysis of Markov models. J. Chem. Theory Comput. 11, 5525\u20135542 (2015).","journal-title":"J. Chem. Theory Comput."},{"key":"30865_CR49","doi-asserted-by":"publisher","first-page":"7271","DOI":"10.1073\/pnas.0832180100","volume":"100","author":"M Hsu","year":"2003","unstructured":"Hsu, M. et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl Acad. Sci. USA 100, 7271\u20137276 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"30865_CR50","doi-asserted-by":"publisher","first-page":"10149","DOI":"10.1073\/pnas.0403519101","volume":"101","author":"C Logvinoff","year":"2004","unstructured":"Logvinoff, C. et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc. Natl Acad. Sci. USA 101, 10149\u201310154 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"30865_CR51","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1172\/JCI78794","volume":"125","author":"JR Bailey","year":"2015","unstructured":"Bailey, J. R. et al. Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. J. Clin. Invest. 125, 437\u2013447 (2015).","journal-title":"J. Clin. Invest."},{"key":"30865_CR52","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1128\/JVI.02700-15","volume":"90","author":"RA Urbanowicz","year":"2015","unstructured":"Urbanowicz, R. A. et al. A diverse panel of hepatitis C virus glycoproteins for use in vaccine research reveals extremes of monoclonal antibody neutralization resistance. J. Virol. 90, 3288\u20133301 (2015).","journal-title":"J. Virol."},{"key":"30865_CR53","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1053\/j.gastro.2009.02.080","volume":"136","author":"KA Dowd","year":"2009","unstructured":"Dowd, K. A., Netski, D. M., Wang, X. H., Cox, A. L. & Ray, S. C. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 136, 2377\u20132386 (2009).","journal-title":"Gastroenterology"},{"key":"30865_CR54","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1107\/S0907444910048675","volume":"67","author":"TG Battye","year":"2011","unstructured":"Battye, T. G., Kontogiannis, L., Johnson, O., Powell, H. R. & Leslie, A. G. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr. D. Biol. Crystallogr. 67, 271\u2013281 (2011).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"30865_CR55","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1107\/S0907444913000061","volume":"69","author":"PR Evans","year":"2013","unstructured":"Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta Crystallogr. D. Biol. Crystallogr. 69, 1204\u20131214 (2013).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"30865_CR56","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"30865_CR57","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D. Biol. Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"30865_CR58","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1107\/S0907444909042073","volume":"66","author":"VB Chen","year":"2010","unstructured":"Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D. Biol. Crystallogr. 66, 12\u201321 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"30865_CR59","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1515\/bchm3.1989.370.1.263","volume":"370","author":"HD Kratzin","year":"1989","unstructured":"Kratzin, H. D. et al. The primary structure of crystallizable monoclonal immunoglobulin IgG1 Kol. II. Amino acid sequence of the L-chain, gamma-type, subgroup I. Biol. Chem. Hoppe Seyler 370, 263\u2013272 (1989).","journal-title":"Biol. Chem. Hoppe Seyler"},{"key":"30865_CR60","doi-asserted-by":"crossref","unstructured":"Wang, L. et al. Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the middle east respiratory syndrome coronavirus spike glycoprotein to avoid neutralization escape. J. Virol. 92, e02002-17 (2018).","DOI":"10.1128\/JVI.02002-17"},{"key":"30865_CR61","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1074\/jbc.M115.672790","volume":"291","author":"RN Gunawardane","year":"2016","unstructured":"Gunawardane, R. N. et al. Agonistic human antibodies binding to lecithin-cholesterol acyltransferase modulate high density lipoprotein metabolism. J. Biol. Chem. 291, 2799\u20132811 (2016).","journal-title":"J. Biol. Chem."},{"key":"30865_CR62","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1126\/science.1246135","volume":"343","author":"RK Grover","year":"2014","unstructured":"Grover, R. K. et al. A structurally distinct human mycoplasma protein that generically blocks antigen-antibody union. Science 343, 656\u2013661 (2014).","journal-title":"Science"},{"key":"30865_CR63","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/emboj.2008.179","volume":"27","author":"CA Thomson","year":"2008","unstructured":"Thomson, C. A. et al. Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus. EMBO J. 27, 2592\u20132602 (2008).","journal-title":"EMBO J."},{"key":"30865_CR64","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41564-019-0411-z","volume":"4","author":"Q Wang","year":"2019","unstructured":"Wang, Q. et al. Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus. Nat. Microbiol. 4, 1231\u20131241 (2019).","journal-title":"Nat. Microbiol."},{"key":"30865_CR65","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00401-017-1705-y","volume":"133","author":"G Pascual","year":"2017","unstructured":"Pascual, G. et al. Immunological memory to hyperphosphorylated tau in asymptomatic individuals. Acta Neuropathol. 133, 767\u2013783 (2017).","journal-title":"Acta Neuropathol."},{"key":"30865_CR66","doi-asserted-by":"crossref","unstructured":"Easterhoff, D. et al. HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions. JCI Insight 5, e131437 (2020).","DOI":"10.1172\/jci.insight.131437"},{"key":"30865_CR67","doi-asserted-by":"crossref","unstructured":"McCarthy, K. R., Raymond, D. D., Do, K. T., Schmidt, A. G. & Harrison, S. C. Affinity maturation in a human humoral response to influenza hemagglutinin. Proc. Natl Acad. Sci. USA 116, 26745\u201326751 (2019).","DOI":"10.1073\/pnas.1915620116"},{"key":"30865_CR68","doi-asserted-by":"publisher","first-page":"4723","DOI":"10.4049\/jimmunol.1402890","volume":"196","author":"S Bryson","year":"2016","unstructured":"Bryson, S. et al. Structures of preferred human IgV genes-based protective antibodies identify how conserved residues contact diverse antigens and assign source of specificity to CDR3 loop variation. J. Immunol. 196, 4723\u20134730 (2016).","journal-title":"J. Immunol."},{"key":"30865_CR69","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.immuni.2018.01.005","volume":"48","author":"E Goodwin","year":"2018","unstructured":"Goodwin, E. et al. Infants infected with respiratory syncytial virus generate potent neutralizing antibodies that lack somatic hypermutation. Immunity 48, 339\u2013349.e5 (2018).","journal-title":"Immunity"},{"key":"30865_CR70","doi-asserted-by":"crossref","unstructured":"Snir, O. et al. Stereotyped antibody responses target posttranslationally modified gluten in celiac disease. JCI Insight 2, e93961 (2017).","DOI":"10.1172\/jci.insight.93961"},{"key":"30865_CR71","doi-asserted-by":"publisher","first-page":"e1006935","DOI":"10.1371\/journal.ppat.1006935","volume":"14","author":"HG Jones","year":"2018","unstructured":"Jones, H. G. et al. Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies. PLoS Pathog. 14, e1006935 (2018).","journal-title":"PLoS Pathog."},{"key":"30865_CR72","doi-asserted-by":"publisher","first-page":"e1008373","DOI":"10.1371\/journal.ppat.1008373","volume":"16","author":"D Oyen","year":"2020","unstructured":"Oyen, D. et al. Structure and mechanism of monoclonal antibody binding to the junctional epitope of Plasmodium falciparum circumsporozoite protein. PLoS Pathog. 16, e1008373 (2020).","journal-title":"PLoS Pathog."},{"key":"30865_CR73","doi-asserted-by":"publisher","first-page":"e1008736","DOI":"10.1371\/journal.ppat.1008736","volume":"16","author":"X Ye","year":"2020","unstructured":"Ye, X. et al. Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step. PLoS Pathog. 16, e1008736 (2020).","journal-title":"PLoS Pathog."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30865-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30865-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30865-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T17:27:13Z","timestamp":1669310833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30865-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["30865"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-30865-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,8]]},"assertion":[{"value":"22 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.E.C. has served as a consultant for Luna Innovations, Merck, and GlaxoSmithKline, is a member of the Scientific Advisory Board of Meissa Vaccines, and is the Founder of IDBiologics. The Crowe laboratory at Vanderbilt University Medical Center has received unrelated sponsored research agreements from Takeda Pharmaceuticals, IDBiologics and AstraZeneca. Some human monoclonal antibodies in this paper are described in International Patent Application No. PCT\/US2018\/029315 entitled \u201cBroadly Neutralizing Antibodies Against Hepatitis C Virus\u201d, filed by Vanderbilt University on behalf of Vanderbilt and Johns Hopkins University; JEC, AIF and JRB are listed as inventors. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3178"}}